L’Oréal acquires majority stake in British skincare brand Medik8
Press Hub UCapital
Share:
L’Oréal Group has announced an agreement to acquire a majority stake in British skincare brand Medik8, renowned for its vitamin C and retinol-based products. The acquisition will further strengthen L’Oréal’s portfolio of premium skincare brands.
Private equity firm Inflexion will retain a minority stake in Medik8. The financial terms of the transaction have not been disclosed. Elliot Isaacs, founder of Medik8, will remain on the board, and the current management team will stay in place to ensure continuity following the acquisition.
Medik8 is best known for its iconic Crystal Retinal serum and its “CSA philosophy”: Vitamin C and sunscreen in the morning, Vitamin A at night. Backed by scientific research and innovation, the brand offers high-quality skincare products formulated with carefully selected ingredients to deliver “results without compromise.” Staying true to its professional roots, Medik8 has evolved into a diversified omnichannel business, partnering with top online and offline retailers across Europe and expanding its footprint in the United States.
Cyril Chapuy, President of L’Oréal LUXE, stated: “We share a strong belief in Medik8’s global potential and are excited to embark on this journey together to build a powerful and impactful brand presence worldwide.”
According to Simon Coble, CEO of Medik8, the deal allows the brand to “join forces with a company that shares our vision for future growth and whose core values align with our deep commitment to science, innovation, and, above all, delivering results without compromise.”
L’Oréal will begin consolidating Medik8’s sales following the transaction's closing. The agreement also includes an option for L’Oréal to acquire the remaining minority-held shares at a later date.
Private equity firm Inflexion will retain a minority stake in Medik8. The financial terms of the transaction have not been disclosed. Elliot Isaacs, founder of Medik8, will remain on the board, and the current management team will stay in place to ensure continuity following the acquisition.
Medik8 is best known for its iconic Crystal Retinal serum and its “CSA philosophy”: Vitamin C and sunscreen in the morning, Vitamin A at night. Backed by scientific research and innovation, the brand offers high-quality skincare products formulated with carefully selected ingredients to deliver “results without compromise.” Staying true to its professional roots, Medik8 has evolved into a diversified omnichannel business, partnering with top online and offline retailers across Europe and expanding its footprint in the United States.
Cyril Chapuy, President of L’Oréal LUXE, stated: “We share a strong belief in Medik8’s global potential and are excited to embark on this journey together to build a powerful and impactful brand presence worldwide.”
According to Simon Coble, CEO of Medik8, the deal allows the brand to “join forces with a company that shares our vision for future growth and whose core values align with our deep commitment to science, innovation, and, above all, delivering results without compromise.”
L’Oréal will begin consolidating Medik8’s sales following the transaction's closing. The agreement also includes an option for L’Oréal to acquire the remaining minority-held shares at a later date.